Edwards Lifesciences Corp (NYSE:EW) CEO Michael A. Mussallem sold 32,800 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, December 19th. The stock was sold at an average price of $114.82, for a total value of $3,766,096.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Michael A. Mussallem also recently made the following trade(s):

  • On Monday, November 20th, Michael A. Mussallem sold 32,900 shares of Edwards Lifesciences stock. The stock was sold at an average price of $106.86, for a total value of $3,515,694.00.
  • On Monday, October 30th, Michael A. Mussallem sold 32,900 shares of Edwards Lifesciences stock. The stock was sold at an average price of $100.93, for a total value of $3,320,597.00.

Shares of Edwards Lifesciences Corp (NYSE:EW) traded down $0.60 during trading hours on Wednesday, reaching $114.32. The company had a trading volume of 950,400 shares, compared to its average volume of 1,643,785. Edwards Lifesciences Corp has a 12 month low of $86.55 and a 12 month high of $121.45. The firm has a market cap of $24,319.36, a price-to-earnings ratio of 31.83, a P/E/G ratio of 2.06 and a beta of 0.51. The company has a quick ratio of 2.76, a current ratio of 3.49 and a debt-to-equity ratio of 0.33.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Tuesday, October 24th. The medical research company reported $0.84 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.86 by ($0.02). Edwards Lifesciences had a net margin of 22.47% and a return on equity of 27.22%. The business had revenue of $821.50 million for the quarter, compared to analyst estimates of $833.85 million. During the same period in the prior year, the company earned $0.68 earnings per share. The company’s quarterly revenue was up 11.1% on a year-over-year basis. equities analysts predict that Edwards Lifesciences Corp will post 3.76 earnings per share for the current fiscal year.

Edwards Lifesciences declared that its Board of Directors has initiated a stock buyback plan on Thursday, December 7th that allows the company to buyback $1.00 billion in outstanding shares. This buyback authorization allows the medical research company to purchase shares of its stock through open market purchases. Shares buyback plans are often a sign that the company’s board of directors believes its stock is undervalued.

Several equities analysts have recently weighed in on EW shares. BidaskClub downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Friday, August 25th. William Blair reissued an “outperform” rating on shares of Edwards Lifesciences in a research report on Monday, August 28th. BMO Capital Markets reissued a “buy” rating and set a $132.00 target price on shares of Edwards Lifesciences in a research report on Friday, September 1st. Royal Bank of Canada reissued a “buy” rating and set a $130.00 target price on shares of Edwards Lifesciences in a research report on Friday, September 1st. Finally, Zacks Investment Research downgraded Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 26th. Six analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $126.43.

A number of large investors have recently made changes to their positions in EW. Koch Industries Inc. increased its holdings in shares of Edwards Lifesciences by 28,363.1% in the second quarter. Koch Industries Inc. now owns 1,397,254 shares of the medical research company’s stock valued at $1,386,000 after purchasing an additional 1,392,345 shares during the period. Artisan Partners Limited Partnership increased its holdings in shares of Edwards Lifesciences by 90.6% in the second quarter. Artisan Partners Limited Partnership now owns 1,278,532 shares of the medical research company’s stock valued at $151,174,000 after purchasing an additional 607,784 shares during the period. Janus Henderson Group PLC increased its holdings in shares of Edwards Lifesciences by 1,135.0% in the third quarter. Janus Henderson Group PLC now owns 619,703 shares of the medical research company’s stock valued at $67,739,000 after purchasing an additional 569,525 shares during the period. Old Mutual Global Investors UK Ltd. increased its holdings in shares of Edwards Lifesciences by 83.0% in the third quarter. Old Mutual Global Investors UK Ltd. now owns 1,100,885 shares of the medical research company’s stock valued at $120,337,000 after purchasing an additional 499,436 shares during the period. Finally, Wells Fargo & Company MN increased its holdings in shares of Edwards Lifesciences by 20.2% in the third quarter. Wells Fargo & Company MN now owns 2,548,282 shares of the medical research company’s stock valued at $278,553,000 after purchasing an additional 429,022 shares during the period. 81.00% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This report was first published by Watch List News and is the property of of Watch List News. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://www.watchlistnews.com/edwards-lifesciences-corp-ew-ceo-michael-a-mussallem-sells-32800-shares/1774981.html.

About Edwards Lifesciences

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.